| BIO-CONVERT-A-S |
BIO-CONVERT-A-S |
92%
|
On November 11, 2024, the Company entered into an agreement with Bio-Convert A/S to acquire 100% of the outstanding shares of Bio-Convert in exchange for 12,000,000 restricted shares of the Company’s… |
| OROCIDIN-A-S |
OROCIDIN-A-S |
92%
|
On November 12, 2024, the Company acquired the remaining 5.3 % of the outstanding shares of Orocidin A/S through the issuance of 200,000 shares at $ 3.25 per share, or $ 443,708 of the Company’s Comm… |
| BIO-CONVERT |
BIO-CONVERT |
90%
|
On November 11, 2024, the Company entered into an agreement with Bio-Convert to acquire 100 % of the outstanding shares of Bio-Convert in exchange for 12,000,000 shares of the Company’s Common Stock. |
| ESG-ADVISOR-GROUP-L-L-C |
ESG-ADVISOR-GROUP-L-L-C |
90%
|
On November 27, 2024, the Company entered into a Professional Relations and Consulting Agreement with ESG Advisor Group, L.L.C. (“ESG”) for the provisions of investor relations and related services. |
| GOOGLE-ENTERPRISE |
GOOGLE-ENTERPRISE |
90%
|
We utilize well-known cloud-based technologies and service providers such as Microsoft Office, and Google enterprise to provide protection against cybersecurity threats. |
| MICROSOFT-OFFICE |
MICROSOFT-OFFICE |
90%
|
We utilize well-known cloud-based technologies and service providers such as Microsoft Office, and Google enterprise to provide protection against cybersecurity threats. |
| OROCIDIN |
OROCIDIN |
90%
|
On November 12, 2024, the Company entered into an agreement with Orocidin to acquire the remaining 29,663 outstanding shares, or approximately 5 %, of Orocidin. In exchange, the Company issued 200,00… |
| CONSULTING-FIRM |
CONSULTING-FIRM |
80%
|
Effective November 27, 2024, the Company entered into a consulting agreement with an advisory firm that will continue through November 30, 2025. |
| DARLINGTON-GROUP-LLC |
DARLINGTON-GROUP-LLC |
80%
|
On October 1, 2025, the Company entered into a consulting agreement with Darlington Group, LLC, which is controlled by Andrew Ritter, a member of the Company’s board of directors. |
| ALTERAL |
ALTERAL |
70%
|
In October 2025, the Company, through its subsidiary NoviThera, purchased intellectual property from Alteral in exchange for 49.9 % equity stake in NoviThera, to research and develop a novel and unique M |
| GK-PARTNERS-APS |
GK-PARTNERS-APS |
70%
|
Effective April 1, 2022, we issued to GK Partners ApS ("GK Partners") , for financial services, a warrant (the "2022 GK Warrant") to purchase up to 600,000 shares of our Common Stock at an exercise p… |
